nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study
|
Munblit, Daniel |
|
|
10 |
7 |
p. 715-724 |
artikel |
2 |
2022 American Thoracic Society International Conference
|
Venkatesan, Priya |
|
|
10 |
7 |
p. e66-e67 |
artikel |
3 |
Correction to Lancet Respir Med 2022; 10: 650–60
|
|
|
|
10 |
7 |
p. e72 |
artikel |
4 |
Correction to Lancet Respir Med 2022; 10: 679–88
|
|
|
|
10 |
7 |
p. e72 |
artikel |
5 |
Correction to Lancet Respir Med 2022; published online April 27. https://doi.org/10.1016/S2213-2600(22)00161-8
|
|
|
|
10 |
7 |
p. e72 |
artikel |
6 |
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
|
Tartof, Sara Y |
|
|
10 |
7 |
p. 689-699 |
artikel |
7 |
Early-phase clinical trials in a pandemic: learning from the response to COVID-19
|
Horsley, Alex |
|
|
10 |
7 |
p. 625-627 |
artikel |
8 |
E-cigarette company tactics in sports advertising
|
Fowler, Stephen |
|
|
10 |
7 |
p. 634-636 |
artikel |
9 |
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
|
Wechsler, Michael E |
|
|
10 |
7 |
p. 650-660 |
artikel |
10 |
From smoking to vaping: a new environmental threat?
|
Pourchez, Jérémie |
|
|
10 |
7 |
p. e63-e64 |
artikel |
11 |
Future threats from coronaviruses
|
Venkatesan, Priya |
|
|
10 |
7 |
p. e69 |
artikel |
12 |
High-flow nasal oxygen alone or alternating with non-invasive ventilation in critically ill immunocompromised patients with acute respiratory failure: a randomised controlled trial
|
Coudroy, Rémi |
|
|
10 |
7 |
p. 641-649 |
artikel |
13 |
How repeated influenza vaccination effects might apply to COVID-19 vaccines
|
Thompson, Mark G |
|
|
10 |
7 |
p. 636-638 |
artikel |
14 |
Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants
|
Tartof, Sara Y |
|
|
10 |
7 |
p. e61-e62 |
artikel |
15 |
Long COVID: aiming for a consensus
|
Munblit, Daniel |
|
|
10 |
7 |
p. 632-634 |
artikel |
16 |
Myopericarditis after COVID-19 vaccination: unexpected but not unprecedented
|
Ryan, Margaret |
|
|
10 |
7 |
p. 624-625 |
artikel |
17 |
Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis
|
Ling, Ryan Ruiyang |
|
|
10 |
7 |
p. 679-688 |
artikel |
18 |
Natural language processing and detecting delirium
|
Burki, Talha |
|
|
10 |
7 |
p. 639 |
artikel |
19 |
Post-COVID-19 condition in children: a COS is urgently needed
|
Munblit, Daniel |
|
|
10 |
7 |
p. 628-629 |
artikel |
20 |
Pulmonary hypertension in Europe: a call to action
|
Burki, Talha |
|
|
10 |
7 |
p. e65 |
artikel |
21 |
The COVID-19 continuum of illness
|
Herridge, Margaret S |
|
|
10 |
7 |
p. 630-631 |
artikel |
22 |
The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial
|
Tiddens, Harm A W M |
|
|
10 |
7 |
p. 669-678 |
artikel |
23 |
The future of Paxlovid for COVID-19
|
Burki, Talha |
|
|
10 |
7 |
p. e68 |
artikel |
24 |
The hidden costs of big tobacco
|
The Lancet Respiratory Medicine, |
|
|
10 |
7 |
p. 623 |
artikel |
25 |
The quest for more COVID-19 vaccinations in Africa
|
Makoni, Munyaradzi |
|
|
10 |
7 |
p. e70-e71 |
artikel |
26 |
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study
|
Kraft, Monica |
|
|
10 |
7 |
p. 661-668 |
artikel |
27 |
The Wuhan lockdown
|
Burki, Talha |
|
|
10 |
7 |
p. 640 |
artikel |
28 |
Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19
|
Casey, Jonathan D |
|
|
10 |
7 |
p. 700-714 |
artikel |